CliffBio
small molecule

TEVETEN HCT

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameTEVETEN HCT
Active ingredientEPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE
Strength600MG;12.5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2001
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TEVETEN HCT patent cliff — loss of exclusivity — | CliffBio